

REMARKS


Reconsideration of the rejection is requested.

Bewick discloses only formulations containing many active ingredients, one of which is "folic acid." There is no mention made anywhere of use in the formulation of any sodium or calcium salt of a derivative of a different compound entirely, dyhydrofolic acid or tetrahydrofolic acid. Clearly, there is no anticipation. Similarly, there is no obviousness because there is nothing of record motivating a skilled worker to employ the calcium or sodium salts of the different compounds in place of the folic acid of the prior art. Thus, all rejections should be withdrawn.

The new claims are based on the examples and are drawn to a variety of sub-aspects of the invention.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: July 3, 2003

AJZ:NEK/jph
K:\Merck\1942\04-03-03 reply.wpd